Analyst Notes: It's a tale of two regions when it comes to prescription barriers in the multiple myeloma market

Two reports out from FirstView examine the way market barriers such as, cost, market access, patient preferences, guidelines and recommendations, and more, affect the way medical oncologists and haematologists in the US and the EU5 countries (France, Germany, Italy, Spain and the UK) prescribe treatments for multiple myeloma.

Though unrelated to safety or efficacy, market barriers nonetheless influence 16 percent of prescriptions in the US, a number that rises to 19 percent in the EU5 countries. Most brands gain and lose market share as a result, but the reports show that only a few are net winners.

Based on surveys with medical oncologists and haematologists, FirstView's Market Access Impact: Multiple Myeloma 2017 reports for the US and EU5 cover up to nine multiple myeloma brands; Darzalex, Farydak, Kyprolis, Imnovid/Pomalyst, Revlimid, Thalomid/Thalidomide and Velcade are in the EU5 reports, and Ninlaro and Empliciti are also included to this list for the US report.

The reports show how seven different market barriers affect each brand's market share, and reveal which competitors each brand loses share to, and takes it from. Companies can download the reports directly from FirstView, saving them the time and expense of commissioning bespoke research.

In the US, most brands lose out, with seven of the nine surveyed brands seeing a net loss due to prescribing barriers. There's a clear leader in the US in terms of prescriptions, but some other brands can't catch a break. This report will tell you which brand sees a net share gain from every other surveyed brand, and which one sees a net loss to every other brand. Moreover, no single barrier is to blame, with up to 20 percent of surveyed doctors experiencing two or more barriers with the surveyed brands, with some experiencing three barriers. Perception is also an issue. Over 30 percent doctors wouldn't consider prescribing one of the brands, a fact that needs resolving. Cost is a huge problem for three brands; between 25 percent to 35 percent of doctors experience cost barriers with these three brands, which is 10 percent more than the leading competitor.

In contrast to the US, things in the EU5 markets aren't as clear cut. Of the seven brands included in the survey, four gain market share and three lose market share. Where does your brand come in the pecking order? Moreover, cost isn't the biggest barrier. While treatment costs do have an impact on prescribing patterns, two other barriers have more of an impact. In the EU5 markets, understanding the fine margins could be the difference between success and failure. Knowing what commercial levers to pull could be critical.

Full reports available from FirstView

These and many other insights, along with the full survey results are available from the FirstView web site.

Interested parties can purchase and download FirstView Market Access Impact: Multiple Myeloma 2017 for the US and EU5 markets directly from the FirstView reports store.

Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.